Laryngeal Cancer Market

Market Overview:

The 7 major laryngeal cancer markets reached a value of US$ 2.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.

The laryngeal cancer market has been comprehensively analyzed in IMARC's new report titled "Laryngeal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Laryngeal cancer refers to a type of oncological disease that originates in the larynx (voice box), which plays a crucial role in breathing, swallowing, and producing sounds for speech. There are two main types of this illness, including squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is the most prevalent form and arises from the thin, flat cells lining the larynx, whereas adenocarcinoma begins in the glandular cells of the larynx and is less common in patients. Individuals suffering from the ailment may experience hoarseness or changes in voice, a persistent cough, a sore throat, difficulty swallowing, fatigue, ear pain, unexplained weight loss, a lump or swelling in the neck, etc. Laryngeal cancer is typically diagnosed through a combination of medical history evaluation, physical examination, and various diagnostic tests. A healthcare provider may also perform an endoscopy to evaluate the larynx by visualizing the vocal cords and surrounding tissues. Numerous other imaging studies, such as computed tomography (CT) scans, magnetic resonance imaging, X-rays, etc., are utilized to help in determining the extent and stage of cancer.

The increasing utilization of tobacco and alcohol, which cause irritation and damage to the tissues and cells of the larynx, is primarily driving the laryngeal cancer market. Additionally, the rising incidence of several associated risk factors, including a weakened immune system, human papillomavirus infections, genetic mutations, advancing age, etc., is also propelling the market growth. Besides this, the emerging popularity of checkpoint inhibitors, such as pembrolizumab and nivolumab, which boost the immune response to recognize and fight against cancerous cells, is acting as another significant growth-inducing factor. Furthermore, the inflating adoption of artificial larynx devices for patients who have undergone laryngectomy is also bolstering the market growth. These devices produce a sound that can be used to articulate speech, thereby offering flexibility in communication to individuals suffering from this condition. Moreover, the escalating application of robotic-assisted surgery, on account of its numerous benefits, such as improving the accuracy of tumor removal, preserving normal vocal cord function, and maintaining speech quality, is expected to drive the laryngeal cancer market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the laryngeal cancer market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for laryngeal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the laryngeal cancer market in any manner.

Key Highlights:

• Laryngeal cancer affects 184,615 people worldwide each year, accounting for 1.1% of all cancer diagnoses and 99,840 fatalities (1% of all cancer-related deaths).
• The majority of persons diagnosed with laryngeal cancer are 55 or older, with an average age of around 66.
• Laryngeal cancer is more prevalent in men than in women. Black males are more prone to developing and dying from laryngeal cancer than white men.
• Cigarette smoking and alcohol addiction are responsible for approximately 90% of global laryngeal cancer deaths.
• Laryngeal cancer is the most frequent malignancy in otolaryngology, accounting for 30-40% of head and neck cancers.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the laryngeal cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the laryngeal cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current laryngeal cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the laryngeal cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the laryngeal cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the laryngeal cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of laryngeal cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of laryngeal cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of laryngeal cancer by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with laryngeal cancer across the seven major markets?
• What is the size of the laryngeal cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of laryngeal cancer?
• What will be the growth rate of patients across the seven major markets?
   

Laryngeal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for laryngeal cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the laryngeal cancer market?
• What are the key regulatory events related to the laryngeal cancer market?
• What is the structure of clinical trial landscape by status related to the laryngeal cancer market?
• What is the structure of clinical trial landscape by phase related to the laryngeal cancer market?
• What is the structure of clinical trial landscape by route of administration related to the laryngeal cancer market?